FARMACIA HOSPITALARIA最新文献

{"title":"Perspectiva de género en problemas asociados a medicamentos de alto riesgo atendidos en urgencias","authors":"Concepción Marín de la Bárcena,&nbsp;Jesús Ruiz Ramos,&nbsp;Mireia Puig Campmany,&nbsp;María José Otero,&nbsp;Ana Juanes Borrego","doi":"10.1016/j.farma.2026.01.004","DOIUrl":"10.1016/j.farma.2026.01.004","url":null,"abstract":"<div><h3>Objectives</h3><div>To characterize medication-related problems resulting in emergency department attendance involving high-alert medications, paying particular attention to sex-related differences in the type of the problem and medication associated with it.</div></div><div><h3>Methods</h3><div>Retrospective observational study (2021–2022) based on the medical history at discharge, including adult patients seeking emergency department due to medication-related problems as a primary or secondary diagnosis. Patient grouping was performed according to the class of medication implicated in the event, as defined by the reference list of high-alert drugs for chronic patients (HAMC list). Sociodemographic and clinical baseline variables were collected. To explore gender differences in the type of problem and drug involved, statistical analysis included binomial tests and binary logistic regression with odds ratio estimation.</div></div><div><h3>Results</h3><div>Among the 1,611 adult patients admitted to the emergency department with adverse events associated with a medication problem, 1,028 (64%) involved a high-alert medication. Women with moderate- and high-risk comorbidity showed a significative greater incidence of medication-related problems. Gender differences were particularly notable for events associated with loop diuretics (136 women [70%] vs 57 men [30%], <em>p</em> = 0.000); antipsychotics (30 women [65%] vs 16 men [35%], <em>p</em> = 0.039); opioids (37 women [73%] vs 11 men [27%], <em>p</em> = 0.000] and digoxin (22 women [81%] vs 5 men [19%], <em>p</em> = 0.02). Women showed a trend toward higher odds of experiencing unintentional drug poisoning (OR = 2.5; 95% CI: 0.786–8.356; <em>p</em> = 0.119). In contrast, non-adherence to prescribed high-alert medications occurred with greater frequency in men (OR = 0.711, 95% CI: 0.473–1.070; <em>p</em> = 0.102).</div></div><div><h3>Conclusions</h3><div>A considerable proportion of medication-related problems that lead to emergency room attendance involve high-risk medications, and the type of problem presented and the type of drug involved differ between sexes. Findings highlight that addressing gender differences, especially with regard to high-risk medicines, could be crucial in moving toward safer and more equitable healthcare.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 240-246"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146776780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] El papel de las herramientas digitales y la inteligencia artificial en el apoyo a los programas de optimización de antimicrobianos: protocolo de estudio para una revisión sistemática","authors":"Carlos José Cortés Sánchez,&nbsp;Fernando Salazar González,&nbsp;José María Gómez Portolés,&nbsp;Josefina Giménez Castellanos,&nbsp;Mónica Climente Martí","doi":"10.1016/j.farma.2026.02.014","DOIUrl":"10.1016/j.farma.2026.02.014","url":null,"abstract":"<div><h3>Introduction</h3><div>Since the post-antibiotic era, there has been significant difficulty in treating infectious diseases due to the increase in antimicrobial resistance, the scarcity of new antimicrobials, and the complexity of the healthcare system. The World Health Organization (WHO) recognized it as one of the main public health problems.</div><div>To mitigate this issue, Antimicrobial Stewardship Programs (ASPs) have been established in hospital settings and in primary care, through multidisciplinary teams with specific objectives and measurable results. However, their implementation faces multiple challenges.</div><div>Digital tools and artificial intelligence (AI) can enhance these ASPs, contributing to the discovery of new molecules, the identification of resistance patterns, and improvements in infection control and prevention.</div></div><div><h3>Objective</h3><div>To analyze the role of digital tools and AI in the interventions carried out by hospital-based ASP teams to improve established outcomes.</div></div><div><h3>Material and methods</h3><div>This protocol follows the PRISMA-P methodology and has been registered in PROSPERO (ID: CRD42024601221). A literature search will be conducted in PubMed, Scopus, and the Cochrane Library (2014–2024); gray literature will subsequently be reviewed in Google Scholar. Articles (clinical trials, interventional and observational) involving hospitalized adult patients requiring antimicrobial treatment will be included. The risk of bias will be assessed according to the study type, and methodological quality will be evaluated using the GRADE scale. Two independent researchers will perform study selection, quality assessment, and data extraction. Discrepancies will be resolved by consensus or through the intervention of a third researcher.</div></div><div><h3>Discussion</h3><div>Previous studies highlight the role of ASPs and digital tools in antimicrobial optimization. However, the difficulty and difference in the degree of implementation have also become apparent. The heterogeneity of interventions and indicators could be a limiting factor for conducting a meta-analysis. Despite these limitations, this systematic review will provide a better understanding of the potential use of digital tools and AI in hospital-based ASPs.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T273-T278"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147515621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Cutting-edge healthcare and Hospital Pharmacy","authors":"Raquel Yotti","doi":"10.1016/j.farma.2026.06.002","DOIUrl":"10.1016/j.farma.2026.06.002","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T215-T216"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148284632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Optimización del intervalo de administración y persistencia con faricimab en la degeneración macular asociada a la edad: un estudio observacional en la práctica clínica real","authors":"Silvia Cornejo-Uixeda,&nbsp;Joaquín Borrás-Blasco,&nbsp;Alejandro Valcuende-Rosique,&nbsp;Leonor Perez Gil,&nbsp;Nuria Monteagudo-Martinez,&nbsp;Virginia Merino","doi":"10.1016/j.farma.2026.02.009","DOIUrl":"10.1016/j.farma.2026.02.009","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate treatment persistence and dosing interval extension with faricimab in neovascular age-related macular degeneration (nAMD) in real-world practice.</div></div><div><h3>Methods</h3><div>Retrospective observational study conducted in a tertiary hospital (March 2024–March 2025). Patients receiving faricimab (treatment-naïve or pre-treated with anti-VEGF therapy), with ≥<!--> <!-->1 post-loading dose, were included. Dosing intervals were analyzed at baseline, 6 and 12 months, Adherence was assessed with the medication possession ratio (MPR), with &gt;<!--> <!-->80% considered adherent. Persistence was defined as the time from treatment initiation to discontinuation or end of follow-up. Persistence was estimated using Kaplan–Meier survival analysis.</div></div><div><h3>Results</h3><div>We included 129 patients (148 eyes), mean age 74.5 ± 8.85 years; 55% were female. A total of 39 patients (30.2%) were treatment-naïve and 90 (69.8%) were pretreated. At 12 months, 48.8% of naïve and 55.5% of pretreated patients achieved 8–12 weeks intervals. Mean persistence was 12.2 months (SD 0.2; 95% CI: 11.8–12.6). The median was not reached by the end of the study. Persistence rate was 93% at 6 and 12 months. Only one patient discontinued due to inefficacy. No serious adverse events or endophthalmitis occurred.</div></div><div><h3>Conclusions</h3><div>Faricimab showed excellent persistence and extended dosing intervals in real-world practice. This is the first study specifically evaluating faricimab real-world persistence in nAMD.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T269-T272"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147460451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Artículo traducido] Respuesta a los comentarios sobre el protocolo PSICU-ALTA: primeros pasos para mejorar la prescripción de psicotrópicos tras el alta de la unidad de cuidados intensivos","authors":"Laura Doménech-Moral ,&nbsp;Javier Santader-Reboreda ,&nbsp;Meri Martin-Cerezuela ,&nbsp;Amaia Egüés Lugea ,&nbsp;Marcos Buj Vicente ,&nbsp;Sofía Contreras Medina","doi":"10.1016/j.farma.2026.02.007","DOIUrl":"10.1016/j.farma.2026.02.007","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T288-T289"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147482001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Multidrug-resistant extra-pulmonary tuberculosis in a hemodialysis patient treated with bedaquiline and tedizolid. A case report and a literature review","authors":"Paula Novo González ,&nbsp;Irene Galindo Marín ,&nbsp;Elena García Benayas ,&nbsp;Carmen Mon Mon ,&nbsp;Rafael Torres Perea ,&nbsp;Sara Hernández Egido","doi":"10.1016/j.farma.2025.07.010","DOIUrl":"10.1016/j.farma.2025.07.010","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T285-T287"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147322461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perfil profesional y expectativas de los miembros adheridos al grupo de trabajo de Atención Farmacéutica en Enfermedades Infecciosas de la Sociedad Española de Farmacia Hospitalaria","authors":"Iván Oterino-Moreira,&nbsp;Álvaro-Eloy Monje-López,&nbsp;Beatriz Mejuto,&nbsp;Alba Pau-Parra,&nbsp;Leonor Periañez-Parraga,&nbsp;Sonia Luque","doi":"10.1016/j.farma.2025.09.004","DOIUrl":"10.1016/j.farma.2025.09.004","url":null,"abstract":"<div><h3>Background</h3><div>The Pharmaceutical Care in Infectious Diseases Group (AFinf) is composed of a coordinating group of 11 pharmacists, 1 fellow, 1 resident pharmacist intern, 4 senior consultants and 221 associate members (July 2025). The aim is to understand and describe the profile of the members as a basis for defining future strategic lines to improve their participation.</div></div><div><h3>Methods</h3><div>An online survey was distributed to all AFinf group members, including questions about their professional activity, expectations and potential contributions to the group.</div></div><div><h3>Results</h3><div>The 41.7% of associated professionals participated in the survey. The median length of experience in the area of infectious diseases was 5 years (RIC 2-10). Antimicrobial stewardship programmes represented the main area of expertise (73.9%; 95% CI: 63.2-84.5), followed by pharmacokinetic monitoring (16.9%; 95% CI: 7.8-26.0). The priorities of the adherents were to receive training and education (52.3%; 95% CI: 40.2-64.5%) as well as the need to share doubts and experiences (27.7%; 95% CI: 16.8-38.6). Among the respondents, 50.0% (95% CI: 39.0-61.0) consider that they could contribute ideas and experiences, while 31.3% (95% CI: 21.1-41.4) research/collaborate on projects and 18.7% (95% CI: 10.2-27.3) participate in teaching and other group activities.</div></div><div><h3>Conclusion</h3><div>This study has allowed us to better understand the professional profile of pharmacists who are members of the AFinf group and to analyze their concerns and possible contributions.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 260-264"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146044034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Gender perspective in medication-related problems resulting in emergency department attendance involving high-alert medications","authors":"Concepción Marín de la Bárcena,&nbsp;Jesús Ruiz Ramos,&nbsp;Mireia Puig Campmany,&nbsp;María José Otero,&nbsp;Ana Juanes Borrego","doi":"10.1016/j.farma.2026.03.005","DOIUrl":"10.1016/j.farma.2026.03.005","url":null,"abstract":"<div><h3>Objectives</h3><div>To characterize medication-related problems resulting in emergency department attendance involving high-alert medications, paying particular attention to sex-related differences in the type of the problem and medication associated with it.</div></div><div><h3>Methods</h3><div>Retrospective observational study (2021–2022) based on the medical history at discharge, including adult patients seeking emergency department due to medication-related problems as a primary or secondary diagnosis. Patient grouping was performed according to the class of medication implicated in the event, as defined by the reference list of high-alert drugs for chronic patients (HAMC list). Sociodemographic and clinical baseline variables were collected. To explore gender differences in the type of problem and drug involved, statistical analysis included binomial tests and binary logistic regression with odds ratio estimation.</div></div><div><h3>Results</h3><div>Among the 1,611 adult patients admitted to the emergency department with adverse events associated with a medication problem, 1,028 (64%) involved a high-alert medication. Women with moderate- and high-risk comorbidity showed a significative greater incidence of medication-related problems. Gender differences were particularly notable for events associated with loop diuretics (136 women [70%] vs 57 men [30%], <em>p</em> = 0.000); antipsychotics (30 women [65%] vs 16 men [35%], <em>p</em> = 0.039); opioids (37 women [73%] vs 11 men [27%], <em>p</em> = 0.000] and digoxin (22 women [81%] vs 5 men [19%], <em>p</em> = 0.02). Women showed a trend toward higher odds of experiencing unintentional drug poisoning (OR = 2.5; 95% CI: 0.786–8.356; <em>p</em> = 0.119). In contrast, non-adherence to prescribed high-alert medications occurred with greater frequency in men (OR = 0.711, 95% CI: 0.473–1.070; <em>p</em> = 0.102).</div></div><div><h3>Conclusions</h3><div>A considerable proportion of medication-related problems that lead to emergency room attendance involve high-risk medications, and the type of problem presented and the type of drug involved differ between sexes. Findings highlight that addressing gender differences, especially with regard to high-risk medicines, could be crucial in moving toward safer and more equitable healthcare.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T240-T246"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147822008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Assessment of serum creatinine-based equations for estimating glomerular filtration rate in critically ill patients with or without augmented renal clearance","authors":"Joan Ramon Roma,&nbsp;Natàlia Arranz-Pasqual,&nbsp;Carla Bastida,&nbsp;Dolors Soy","doi":"10.1016/j.farma.2026.04.010","DOIUrl":"10.1016/j.farma.2026.04.010","url":null,"abstract":"<div><h3>Background</h3><div>Serum creatinine-based equations are commonly used to estimate glomerular filtration rate (eGFR) in critically ill patients, despite not having been specifically developed for this population. This study aimed to assess and compare the performance of three widely used serum creatinine-based equations in this setting.</div></div><div><h3>Methods</h3><div>Observational retrospective study conducted in four intensive care units of a tertiary university hospital. The most commonly used serum creatinine-based equations, the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), Modification of Diet in Renal Disease (MDRD-4), and Cockcroft-Gault (CG) equations were compared to the creatinine clearance from 24-hour urine collection (CrCl_24h), used as the reference method. Bland and Altman plots, bias and precision were performed to contrast CrCl_24h values with estimated GFR. Bias and its 95% confidence interval were calculated as the mean difference between the eGFR estimated by each equation and the measured CrCl_24h. Precision was reported as one standard deviation of the bias.</div></div><div><h3>Results</h3><div>A total of 261 patients were included. In patients with CrCl_24h between 0–129 mL/min, no significant differences were observed between equations. However, in patients with augmented renal clearance (15.7%), with a mean CrCl_24h of 180 mL/min, there was a statistically significant bias between the CKD-EPI equation (66.4 mL/min/1,73m²) and both the CG and MDRD-4 equations (24.8 mL/min/m² and 29.3 mL/min/1,73 m², respectively; p &lt; 0.01).</div></div><div><h3>Conclusions</h3><div>This study highlights that the most commonly used equations to estimate glomerular filtration rate in critically ill patients have remarkable limitations compared to creatinine clearance from 24-hour urine collection. In critically ill patients with CrCl_24h between 0-129 mL/min, no significant differences were found between the CG, MDRD-4, and CKD-EPI equations. However, for patients with augmented renal clearance, the CG and MDRD-4 equations performed statistically better than the CKD-EPI equation.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages T253-T259"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148007045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dosing interval optimization and persistence with faricimab in age-related macular degeneration: An observational study in real-world clinical practice","authors":"Silvia Cornejo-Uixeda ,&nbsp;Joaquín Borrás-Blasco ,&nbsp;Alejandro Valcuende-Rosique ,&nbsp;Leonor Perez Gil ,&nbsp;Nuria Monteagudo-Martinez ,&nbsp;Virginia Merino","doi":"10.1016/j.farma.2025.12.002","DOIUrl":"10.1016/j.farma.2025.12.002","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate treatment persistence and dosing interval extension with faricimab in neovascular age-related macular degeneration (nAMD) in real-world practice.</div></div><div><h3>Methods</h3><div>Retrospective observational study conducted in a tertiary hospital (March 2024–March 2025). Patients receiving faricimab (treatment-naïve or pre-treated with anti-VEGF therapy), with ≥<!--> <!-->1 post-loading dose, were included. Dosing intervals were analyzed at baseline, 6 and 12 months, Adherence was assessed with the medication possession ratio (MPR), with &gt;<!--> <!-->80% considered adherent. Persistence was defined as the time from treatment initiation to discontinuation or end of follow-up. Persistence was estimated using Kaplan–Meier survival analysis.</div></div><div><h3>Results</h3><div>We included 129 patients (148 eyes), mean age 74.5 ± 8.85 years; 55% were female. A total of 39 patients (30.2%) were treatment-naïve and 90 (69.8%) were pretreated. At 12 months, 48.8% of naïve and 55.5% of pretreated patients achieved 8–12 weeks intervals. Mean persistence was 12.2 months (SD 0.2; 95% CI: 11.8–12.6). The median was not reached by the end of the study. Persistence rate was 93% at 6 and 12 months. Only one patient discontinued due to inefficacy. No serious adverse events or endophthalmitis occurred.</div></div><div><h3>Conclusions</h3><div>Faricimab showed excellent persistence and extended dosing intervals in real-world practice. This is the first study specifically evaluating faricimab real-world persistence in nAMD.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 4","pages":"Pages 269-272"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145949396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}